IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies
乌龙制药(US:URGN) Prnewswire·2026-08-20 19:05NAZARETH, Israel, Aug. 20, 2026 /PRNewswire/ -- IntraGel Therapeutics, developer of next generation long- acting injectables, today announced an equity investment agreement and a strategic Option and Research License Agreement (the Option Agreement) with UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers. In a related equity investment agreement, UroGen will invest up to $7 million in the equ ...